Endocrinology

NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

Would you consider hormone replacement therapy in young women with germline BRCA1 mutation and history of triple negative breast cancer who underwent bilateral mastectomy and prophylactic bilateral salpingo-oophorectomy?

This situation can feel uncomfortable. Would this feel safer if the patient is s/p mastectomy and had TNBC?

2 Answers available

Do you offer adjuvant bisphosphonates to high-risk premenopausal women on ovarian suppression for early-stage breast cancer who would want to consider pregnancy in the future?

Which agents would you select and for how long would you treat them?

1 Answer available

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?

1 Answer available

Would you re-introduce bisphosphonate or denosumab in a bone-only metastatic ER+ breast cancer patient with history of osteonecrosis of the jaw?

2 Answers available

Papers discussed in this category

J Clin Oncol, 2019 Sep 18

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

Mol Cell Endocrinol, 2021 Jan 26

Hormone replacement therapy after breast cancer: Yes, No or maybe?

Lancet (London, England), 2004-02-07

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.

European journal of cancer (Oxford, England : 1990), 2012 Aug 11

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Lancet,

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

J Clin Oncol, 2022 Jan 18

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

Related Topics in Endocrinology